Introduction {#sec1}
============

The generator-produced positron-emitting isotope gallium-68 (^68^Ga) possesses a decay profile (*t*~1/2~ = 68 min, 90% positron yield, 1.9 MeV) that makes it suitable for molecular imaging with positron emission tomography (PET) using peptide-based targeting agents.^[@ref1]−[@ref3]^ The advent of an approved pharmaceutical grade ^68^Ge/^68^Ga generator^[@ref3]^ (^68^Ge *t*~1/2~ = 270 days) allows hospitals economical access to a PET isotope without expensive cyclotron facilities. Indeed, current clinical use of ^68^Ga tracers for neuroendocrine (^68^Ga-DOTATATE) and prostate (^68^Ga-HBED-PSMA) tumor-targeting radiopharmaceuticals has had significant impact in the management of patients.^[@ref4]−[@ref9]^

The macrocycle 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), utilized in ^68^Ga-DOTATATE, has been extensively used in radiolabeled ^68^Ga^3+^ PET tracers despite the fact that elevated temperatures are required to achieve quantitative radiochemical yield, and some clinical productions of ^68^Ga-DOTATATE require a postsynthetic purification step^[@ref1],[@ref2],[@ref10]−[@ref12]^ which adds undesirable complexity to the radiopharmaceutical preparation, creating a barrier to widespread implementation of ^68^Ga PET. To allow for simplification of labeling, alternative bifunctional chelators for ^68^Ga^3+^ have been designed. These include bifunctional chelators based on 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA and NODAGA),^[@ref13]−[@ref20]^ 1,4,7-triazacyclononane macrocycles substituted with phosphinic acid groups at the amine (TRAP and NOPO),^[@ref21]−[@ref27]^ hexaazamacrobicycles,^[@ref28]^ a pyridyl-substituted DOTA macrocycle (PCTA),^[@ref10],[@ref29]^ bis(2-hydroxybenzyl)ethylenediaminediacetic acid (HBED), and related compounds (notably HBED-CC) possessing phenol, amine, and carboxyl donor groups,^[@ref4],[@ref30]^ substituted 6-amino-perhydrodiazepines (AAZTA),^[@ref31]^ a siderophore-derived macrocyclic chelator with hydroxamate groups (FSC),^[@ref32]^ and an acyclic chelator based on a substituted pyridine carboxylate with an N~4~O~2~ binding mode (DEDPA).^[@ref33]−[@ref35]^ Derivatives of NOTA/NODAGA, TRAP/NOPO, HBED, FSC, AAZTA, and DEDPA conjugates have demonstrated desirable radiolabeling properties, with labeling proceeding at room temperature for all these chelators. We have described a tripodal ligand containing three 1,6-dimethyl-3-hydroxypyridin-4-one groups (H~3~THP-Ac) that, upon loss of three protons, coordinates ^68^Ga^3+^ via 6 O-atoms at pH 6--7 and low ligand concentrations (10 μM) in \<5 min ([Chart [1](#cht1){ref-type="chart"}](#cht1){ref-type="chart"}).^[@ref36]^ This chelator can be radiolabeled quantitatively and faster, at lower chelator concentration and under conditions that are milder^[@ref36]^ (ambient temperature without acidic pH) than other chelators such as DOTA and NOTA that are commonly employed for ^68^Ga^3+^ and that typically require acidic conditions (pH 2--5) and, in the case of DOTA, high temperatures (≥80 °C) to achieve quantitative labeling.^[@ref10]−[@ref13]^ A maleimide derivative of this chelator (for conjugation to thiol groups) has been prepared (H~3~THP-mal, [Chart [1](#cht1){ref-type="chart"}](#cht1){ref-type="chart"}),^[@ref36],[@ref37]68^Ga-labeled conjugates of which demonstrated high in vivo stability over 90 min with respect to metal complex integrity.

![Structures of H~3~THP-Ac and H~3~-THP-mal](bc-2015-00335q_0002){#cht1}

To increase the versatility of this unique chelation system to enable labeling of noncysteine-containing biomolecules, including small proteins and antibodies, new derivatives are required. We report the synthesis of two new tris(hydroxypyridinone) chelators based on 1,6-dimethyl-3-hydroxypyridin-4-one groups that contain pendant isothiocyanates for conjugation to primary amines, and their use for labeling exemplar peptide conjugates with ^68^Ga for PET imaging.

Results {#sec2}
=======

Synthesis and Radiolabeling of Peptide Conjugates {#sec2.1}
-------------------------------------------------

To synthesize H~3~THP-NCS ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), (**1**)^[@ref38]^ was reacted with triethylamine and carbon disulfide in ethanol, to give a precipitated dithiocarbamate intermediate upon addition of water.^[@ref39]^ The precipitated intermediate was resuspended in a solution of carbon disulfide/ethanol and addition of di-*tert*-butyl dicarbonate and a catalytic amount of 4-dimethylaminopyridine resulted in formation of (**2**). Subsequent removal of the benzyl groups with boron trichloride in dichloromethane, followed by addition of trifluoroethanol resulted in H~3~THP-NCS. To synthesize H~3~THP-PhNCS ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), an excess of *p*-phenylene diisothiocyanate and diisopropylethylamine in dimethylformamide were added to a solution of (**1**), followed by isolation of (**3**) using reverse-phase semipreparative high-performance liquid chromatography (HPLC). The benzyl groups of (**3**) were removed using boron trichloride in dichloromethane, followed by addition of methanol, resulting in the bifunctional chelator H~3~THP-PhNCS.

![Synthesis of Tris(hydroxpyridinone) Bifunctional Chelators Containing Isothiocyanate Groups, H~3~THP-NCS (top) and H~3~THP-PhNCS (bottom)](bc-2015-00335q_0006){#sch1}

The α~v~β~3~ integrin-targeting pentapeptide, cyclic(RGDfK) (RGD), was chosen as an appropriately well-characterized peptide targeting vector^[@ref40]^ for conjugation to the new tris(hydroxypyridinone) bifunctional chelators. Both H~3~THP-NCS and H~3~THP-PhNCS were reacted with the primary amine of the lysine side chain of RGD under microwave conditions similar to those often employed for peptide synthesis (dimethyl sulfoxide containing diisopropylethylamine, 120 °C, 300 W, 30 min). Use of dimethylformamide as a solvent in place of dimethyl sulfoxide resulted in precipitation of the bifunctional chelator upon addition of base, and no reaction took place, necessitating the use of dimethyl sulfoxide as a solvent. The reaction products were purified using semipreparative HPLC. Both conjugates H~3~THP-NCS-RGD and H~3~THP-PhNCS-RGD ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a,c) were isolated in 98% purity.

Both peptide derivatives could be radiolabeled with generator-produced eluate that was added either directly from the generator, or eluate that was preconditioned to concentrate activity and remove any contaminating ^68^Ge. In the case of the former, addition of generator-produced ^68^Ga^3+^ (90--110 MBq, Eckert and Ziegler generator) in aqueous HCl (0.1 M, 1 mL) to the tris(hydroxypyridinone) conjugates (10--12 nmol) at ambient temperature, followed by addition of aqueous ammonium acetate (1 M, 300 μL) to obtain solutions of pH ∼ 6.5, provided ^68^Ga-labeled conjugate. Within 2--5 min of addition of ^68^Ga^3+^ to the conjugates, the solutions were subjected to analytical reverse-phase HPLC analysis. Each reaction mixture gave a single peak in the HPLC radiochromatogram ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b,d, red traces), and in these experiments, in which a low activity generator was utilized, the radiochemical yield measured \>99%, with specific activities of 8--9 MBq nmol^--1^.

For radiolabeling conjugates for in vivo studies, a generator eluting higher activities was employed, and eluate was subjected to pretreatment prior to radiolabeling to remove ^68^Ge.^[@ref41]^ Generator-produced ^68^Ga^3+^(800--1000 MBq, iThemba Laboratories generator) was concentrated on an AG 50W × 4 cation exchange cartridge, and eluted with 200 μL 0.9 M HCl in ethanol/water (90%/10%).^[@ref41]^ This volume was diluted in deionized water (800 μL) and directly added to H~3~THP-NCS-RGD and H~3~THP-PhNCS-RGD (∼12 nmol) at ambient temperature, followed immediately by addition of aqueous ammonium acetate (2 M, 400 μL) and saline to obtain solutions of pH ∼ 6.5, resulting in solutions of \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\]. Within 2--5 min of addition of ^68^Ga^3+^ to the conjugates, the solutions were subjected to analytical reverse-phase HPLC and instant thin layer chromatography (ITLC) analysis. Each reaction mixture gave a single major peak in the HPLC radiochromatogram ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)), and under these conditions, the radiochemical yield for all of these reactions was \>95% (determined by ITLC), with specific activities of 60--80 MBq nmol^--1^.

To verify the identity of the radiolabeled products, the ^68^Ga-labeled conjugates and their nonradioactive (^*nat*^Ga) analogs were analyzed using analytical reverse-phase HPLC with UV and sodium iodide scintillation detection. H~3~THP-NCS-RGD eluted earlier than \[^nat/68^Ga(THP-NCS-RGD)\] ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b, black trace, retention time of 7.15 min). Co-elution of \[^*nat*^Ga(THP-NCS-RGD)\] ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b, blue trace, retention time of 7.57 min) with \[^68^Ga(THP-NCS-RGD)\] (red trace, retention time of 7.83 min) confirmed the identity of the radiolabeled compound, with the difference in retention time a result of the configuration of the different detectors in series. Only a single signal was observed in the liquid chromatography/mass spectrometry (LCMS) total ion count chromatogram, corresponding to \[^*nat*^Ga(THP-NCS-RGD)\] ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b, inset). The dipositive ion (\[^*nat*^Ga(THP-NCS-RGD)+2H\]^2+^: {C~65~H~90~N~17~O~17~SGa}^2+^, observed monoisotopic peak = 740.78, calculated = 740.78) was the strongest in the spectrum, but the corresponding tripositive and monopositive species were also observed. Similarly, a solution containing \[^*nat*^Ga(THP-PhNCS-RGD)\] resulted in a signal in the UV chromatogram with a retention time of 8.15 min, matching that of \[^68^Ga(THP-PhNCS-RGD)\] (8.35 min, radiochromatogram), and distinct from H~3~THP-PhNCS-RGD (7.80 min) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}d). A single signal was observed in the LCMS total ion count chromatogram, corresponding to \[^*nat*^Ga(THP-PhNCS-RGD)\], and the major peak in the associated mass spectrum was the dipositive ion (\[^*nat*^Ga(THP-PhNCS-RGD) + 2H\]^2+^: {C~72~H~96~N~19~O~17~S~2~Ga}^2+^, observed monoisotopic peak = 815.80, calculated 815.80). No Ga^3+^ complexes with metal/ligand stoichiometry other than 1:1 were detected in any fraction eluting from the HPLC column in either case.

![(a) H~3~THP-NCS-RGD; (b) HPLC traces (λ~220~) of H~3~THP-NCS-RGD (black) and \[^*nat*^Ga(THP-NCS-RGD)\] (blue), and radio-HPLC trace of \[^68^Ga(THP-NCS-RGD)\] (red). Inset: Mass spectral signal of \[^*nat*^Ga(THP-NCS-RGD) + 2H\]^2+^; (c) H~3~THP-PhNCS-RGD; (d) HPLC traces (λ~220~) of H~3~THP-PhNCS-RGD (black) and \[^*nat*^Ga(THP-PhNCS-RGD)\] (blue), and radio-HPLC trace of \[^68^Ga(THP-PhNCS-RGD)\] (red). Inset: Mass spectral signal of \[^*nat*^Ga(THP-PhNCS-RGD) + 2H\]^2+^.](bc-2015-00335q_0003){#fig1}

Serum stability studies were undertaken to determine whether \[^68^Ga(THP-NCS-RGD)\] or \[^68^Ga(THP-PhNCS-RGD)\] release ^68^Ga^3+^ to endogenous serum proteins. Addition of generator-produced ^68^Ga^3+^ to a solution of human serum resulted in ^68^Ga-bound protein and small molecule adducts that possessed distinct retention times of 5.9, 9.1, and 13.1 min when applied to the size exclusion HPLC column utilized in this study ([Figure S2a](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)). Under the same conditions, the radiolabeled peptide conjugates \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] possessed retention times of 18.1 and 20.2 min, respectively ([Figure S2b,d](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)). Both \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] were incubated in fresh human serum at 37 °C, and at 1 and 4 h, aliquots of these serum solutions were applied directly to the size exclusion HPLC column. Size exclusion chromatograms acquired at 1 and 4 h time points exhibited single signals with the same retention times as the control samples of \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\], indicating that no transchelation of ^68^Ga^3+^ from peptide conjugate to serum constituents occurred in either case ([Figure S2c,e](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)).

In vivo metabolic stability studies were also performed in Balb/c mice to assess whether \[^68^Ga(THP-NCS-RGD)\] or \[^68^Ga(THP-PhNCS-RGD)\] are modified, metabolized, or degraded while in circulation. Blood samples were obtained 20 and 90 min postinjection (PI), the serum fraction was separated from erythrocytes, serum proteins precipitated, and the supernatant applied to an analytical reverse-phase HPLC column. The acquired chromatograms revealed single signals for each trace, and each signal possessed a retention time that matched that of the administered radiotracer ([Figures S3a-c and S4a-c](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)). Urine was also collected and analyzed by reverse-phase HPLC ([Figures S3d and S4d](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)). While signals corresponding to the retention time of the administered radiotracers were observed in the chromatograms for both conjugates, several other broad signals were observed. These data indicated that both \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] were metabolically stable in circulation in vivo over a period of 90 min; however, renal clearance pathways for both radiotracers involved significant metabolism of both \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\].

The half-maximal inhibitory concentration (IC~50~) values of \[Ga(THP-NCS-RGD)\], \[Ga(THP-PhNCS-RGD)\], and RGD were determined using a solid-phase competitive binding assay with ^125^I-echistatin. Binding of ^125^I-echistatin to α~v~β~3~ integrin was inhibited by \[Ga(THP-NCS-RGD)\], \[Ga(THP-PhNCS-RGD)\], and RGD in a concentration-dependent manner demonstrating high binding affinity and specificity of \[Ga(THP-NCS-RGD)\], \[Ga(THP-PhNCS-RGD)\], and RGD for α~v~β~3~ integrin ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The IC~50~ value of \[Ga(THP-NCS-RGD)\] (8.3 ± 1.5 nM) was comparable to that of RGD (8.7 ± 1.6 nM), indicating similar affinity for the α~v~β~3~ integrin receptor. The IC~50~ value of \[Ga(THP-PhNCS-RGD)\] (4.8 ± 0.6 nM) was lower than that of \[Ga(THP-NCS-RGD)\] and RGD, suggesting a higher relative affinity for the α~v~β~3~ integrin receptor. Importantly, IC~50~ values indicated that the tris(hydroxypyridinone) conjugates retain the affinity of the parent peptide for α~v~β~3~ integrin receptors.

###### IC~50~ Values for \[Ga(THP-NCS-RGD)\], \[Ga(THP-PhNCS-RGD)\], and RGD, Determined Using a Solid-Phase Competitive Binding Assay with ^125^I-Echistatin

  compound                IC~50~ (nM) (±standard error)   95% confidence interval (nM)
  ----------------------- ------------------------------- ------------------------------
  \[Ga(THP-NCS-RGD)\]     8.3 ± 1.5                       5.2--11.3
  \[Ga(THP-PhNCS-RGD)\]   4.8 ± 0.6                       3.6--5.9
  RGD                     8.7 ± 1.6                       5.5--11.9

![Mean concentration response curve for ^125^I-echistatin titrated with \[Ga(THP-NCS-RGD)\] (black), \[Ga(THP-PhNCS-RGD)\] (red), and RGD (blue) (*n* = 6 for each concentration; error bars correspond to standard error of the mean).](bc-2015-00335q_0004){#fig2}

Biodistribution of ^68^Ga-Labeled Peptide Conjugates {#sec2.2}
----------------------------------------------------

The biodistribution of \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] was assessed in Balb/c nu/nu mice bearing α~v~β~3~ integrin-positive glioblastoma U87MG tumors (*n* = 3). Each animal was administered 16--21 MBq of tracer (containing ∼1 μg of conjugate) and PET scanned at either 1 or 2 h PI for 10 min, followed by euthanasia and organ harvesting for ex vivo radioactivity counting. To assess specificity of the radiotracer, separate groups of animals were coadministered the tracer and RGD (0.4 mg per animal), followed by scanning, euthanasia, and ex vivo organ counting 1 h PI.

In PET scans of mice administered \[^68^Ga(THP-NCS-RGD)\] 1 h PI ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a), the tumor was visible, with a tumor to background (mediastinum) concentration ratio of 2.76 ± 0.18. The kidneys and liver of all animals were also discernible with a tumor to kidney concentration ratio of 1.03 ± 0.05, and a tumor to liver concentration ratio of 1.59 ± 0.16. There was no evidence of bone uptake being above that of surrounding muscle. Excretion was largely renal and the bladder was associated with the highest levels of activity in all PET images. Images of animals coadministered RGD demonstrated that RGD effectively blocks α~v~β~3~ integrin receptor binding by \[^68^Ga(THP-NCS-RGD)\].

![PET imaging and ex vivo biodistribution of (a) \[^68^Ga(THP-NCS-RGD)\] and (b) \[^68^Ga(THP-PhNCS-RGD)\]. Representative PET maximum intensity projection of Balb/c nu/nu mice bearing a U87MG tumor on right flank at (i) 1 h PI of tracer, (ii) 1 h after coinjection of tracer and RGD, and (iii) 2 h PI of tracer, (iv) ex vivo biodistribution in mice at 1 and 2 h PI of tracer, and 1 h PI of tracer coadministered with RGD (blocked); *n* = 3. Error bars correspond to standard error of the mean.](bc-2015-00335q_0005){#fig3}

The ex vivo biodistribution data of \[^68^Ga(THP-NCS-RGD)\] ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b) were consistent with PET imaging data. In animals administered solely \[^68^Ga(THP-NCS-RGD)\], there was significantly higher radioactivity concentration in the tumor than in animals co-administered \[^68^Ga(THP-NCS-RGD)\] and RGD, indicative of receptor-mediated tumor uptake (2.35 ± 0.06%ID g^--1^, vs 0.62 ± 0.10%ID g^−1^, respectively, mean difference = 1.73%ID g^--1^, 95% CI = 1.45 -- 1.99%ID g^--1^, *p* = 6.00 × 10^--5^. Coadministration of RGD also significantly reduced uptake of the tracer at 1 h PI in the heart, liver, spleen, muscle, and lungs ([Table S1](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)). At both 1 and 2 h PI, the tumor, kidneys, and liver contained the highest concentration of radioactivity ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b). At 2 h PI, blood activity had cleared significantly compared to 1 h PI (0.16 ± 0.04 vs 0.84 ± 0.09%ID g^--1^, respectively), and in all organs and tissues, decay-corrected activity was slightly decreased compared to 1 h PI.

Similarly, PET scans of animals administered \[^68^Ga(THP-PhNCS-RGD)\] demonstrated that \[^68^Ga(THP-PhNCS-RGD)\] accumulated in the tumor, with a tumor to background concentration ratio of 2.34 ± 0.06, and a tumor to liver concentration ratio of 0.91 ± 0.03 at 1 h PI. There was no evidence of bone uptake being above that of surrounding muscle. Ex vivo biodistribution data demonstrated that there was significantly more activity associated with the tumor for animals administered solely \[^68^Ga(THP-PhNCS-RGD)\] 1 h PI (2.86 ± 0.43%ID g^--1^) than for animals coadministered \[^68^Ga(THP-PhNCS-RGD)\] and RGD (0.99 ± 0.12%ID g^--1^, mean difference = 1.87%ID g^--1^, 95% CI = 0.86--2.89%ID g^--1^, *p* = 6.89 × 10^--3^), consistent with α~v~β~3~ integrin receptor mediated tumor uptake. Significantly reduced uptake was also observed for the spleen, liver, and muscle in animals coadministered RGD ([Table S2](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)). In contrast to \[^68^Ga(THP-NCS-RGD)\], uptake of \[^68^Ga(THP-PhNCS-RGD)\] in the tumor, spleen, and liver was slightly higher 2 h PI compared to 1 h PI, while uptake in other organs decreased ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b-iv). Blood activity at 2 h PI (0.25 ± 0.02%ID g^--1^) was lower than that observed at 1 h PI (0.57 ± 0.03%ID g^--1^). Blood activity at 1 h PI in the group coadministered RGD was significantly higher (1.29 ± 0.10%ID g^--1^) than in the group administered only \[^68^Ga(THP-PhNCS-RGD)\] (0.57 ± 0.03%ID g^--1^) ([Table S2](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf)).

Tumor uptake of \[^68^Ga(THP-PhNCS-RGD)\] was higher than that of \[^68^Ga(THP-NCS-RGD)\] at 1 h PI and 2 h PI (1 h: 2.86 ± 0.43 vs 2.35 ± 0.06%ID g^--1^, mean difference = 0.52%ID g^--1^, 95% CI = −0.48--1.51%ID g^--1^, *p* = 0.22; 2 h: 3.32 ± 0.20 vs 1.90 ± 0.21%ID g^--1^, mean difference = 1.41%ID g^--1^, 95% CI = 0.75--2.08%ID g^--1^, *p* = 4.15 × 10^--3^, respectively). This is consistent with the lower IC~50~ value determined for \[Ga(THP-PhNCS-RGD)\] relative to \[Ga(THP-NCS-RGD)\]. The observed higher affinity of \[Ga(THP-PhNCS-RGD)\] (both in the solid-phase binding assay and in vivo) is possibly a result of the greater distance between the tris(hydroxypyridinone) complex and the RGD motif in \[^68^Ga(THP-PhNCS-RGD)\] compared to \[^68^Ga(THP-NCS-RGD)\].

Similarly, accumulation of radioactivity in the liver and spleen is higher in animals administered \[^68^Ga(THP-PhNCS-RGD)\] compared with animals administered ^68^Ga(THP-NCS-RGD)\] at both 1 and 2 h PI. This difference in accumulation of the two tracers in the liver and spleen could be a result of two factors: (i) the increased α~v~β~3~ integrin affinity of \[^68^Ga(THP-PhNCS-RGD)\] relative to \[^68^Ga(THP-NCS-RGD)\], and/or (ii) increased nonspecific uptake of \[^68^Ga(THP-PhNCS-RGD)\] in the liver and spleen compared to \[^68^Ga(THP-NCS-RGD)\]. There is some evidence in support of the latter---in the blockade experiments, uptake of \[^68^Ga(THP-PhNCS-RGD)\] is higher than uptake of \[^68^Ga(THP-NCS-RGD)\] in both the liver (2.68 ± 0.12 vs 1.30 ± 0.16%ID g^--1^) and spleen (0.82 ± 0.03 vs 0.42 ± 0.09%ID g^--1^).

Discussion {#sec3}
==========

Simplicity and efficiency of labeling is a key to wider adoption of ^68^Ga PET in hospitals. The new bifunctional chelators, H~3~THP-NCS and H~3~THP-PhNCS, enable a facile, single-step route for preparation of peptide conjugates containing a tris(hydroxypyridinone) chelator. We chose to attach these new bifunctional chelators to the α~v~β~3~ integrin-targeting peptide RGD to evaluate the radiolabeling and biodistribution profile of a simple tris(hydroxypyridinone) peptide conjugate and to establish whether such conjugates retain their receptor targeting affinity in vivo. Conjugation via the pendant isothiocyanate proceeds under microwave conditions frequently employed in peptide synthesis.^[@ref42]^

The ^68^Ga-radiolabeling of H~3~THP-NCS-RGD and H~3~THP-PhNCS-RGD could be accomplished at ambient temperatures simply by addition of acidic solutions of generator-produced ^68^Ga^3+^ to solutions of the conjugates, followed by addition of ammonium acetate. High radiochemical yields (\>95%) and specific activities (60--80 MBq nmol^--1^) were achieved, circumventing the requirement for postsynthetic purification. These uniquely efficient, simple, and mild radiolabeling properties would afford exceptionally rapid radiochemical synthesis of a ^68^Ga radiopharmaceutical and are conducive to translation to a one-step, kit-based preparation of a peptidic ^68^Ga-labeled radiotracer based on a tris(hydroxypyridinone) conjugate.

Serum and metabolic stability data indicate that both \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] are stable to ^68^Ga^3+^ transchelation to serum proteins, as well as degradation or modification of the conjugates while in circulation, respectively. Furthermore, PET scans and ex vivo biodistribution data in Balb/c nu/nu mice bearing glioblastoma U87MG α~v~β~3~ integrin-positive tumors indicate that both \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] retain affinity for α~v~β~3~ integrin receptors in vivo. Ex vivo biodistribution data are consistent with the expression profile of α~v~β~3~ integrin, which is expressed in tumors including late stage glioblastomas, angiogenesis,^[@ref43]^ and at low levels in normal vascular tissue.^[@ref40]^

Animals coadministered RGD demonstrate that RGD effectively blocks α~v~β~3~ integrin receptor binding by both \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] in tumors, and as such, tumor uptake of the new radiotracers is receptor-mediated. Biodistribution data also indicate significant receptor-mediated uptake in the liver and spleen for both radiotracers, and in the heart, muscle, and lungs for \[^68^Ga(THP-NCS-RGD)\]. Similar decreased uptake in blockade experiments for the liver, spleen, heart, lungs, muscles, adrenals, and intestines has been previously observed with other RGD conjugates labeled with PET isotopes ^68^Ga, ^64^Cu, ^18^F, and ^44^Sc.^[@ref19],[@ref20],[@ref26],[@ref27],[@ref44],[@ref45]^ Tumor uptake of \[^68^Ga(THP-NCS-RGD)\] (1 h: 2.35 ± 0.06%ID g^--1^, 2 h: 1.90 ± 0.21%ID g^--1^) and \[^68^Ga(THP-PhNCS-RGD)\] (1 h: 2.86 ± 0.43, 2 h: 3.32 ± 0.20) is comparable to that of other conjugates of RGD reported in U87MG tumor bearing mice, although generally tumor to nontarget organ ratios, notably the liver, are lower for the tris(hydroxypyridinone) conjugates. ^68^Ga-labeled conjugates of RGD demonstrate receptor-mediated tumor uptake at 1 h PI of 5.19 ± 1.45%ID g^--1^ for ^68^Ga-NODAGA-RGD and 3.47 ± 0.78%ID g^--1^ for ^68^Ga-DOTA-RGD. Similar accumulation is observed for ^64^Cu-labeled analogs.^[@ref20]^ The ^18^F-galacto-RGD PET tracer has an uptake of 1.16%ID g^--1^ 1 h PI, but significantly lower nontarget organ uptake.^[@ref46]^ The dimeric conjugate containing two α~v~β~3~ integrin targeting cyclic(RGDyK) groups, ^68^Ga-NODAGA-E(RGDyK)~2~, demonstrates receptor mediated accumulation, with U87MG tumor uptake measuring 2.23 ± 0.08%ID g^--1^ 1 h PI and liver uptake of 2.97 ± 0.39%ID g^--1^,^[@ref19]^ values comparable to the monomeric tracers described here.

Concluding Remarks {#sec4}
==================

The new bifunctional chelators, H~3~THP-NCS and H~3~THP-PhNCS, enable a facile route for preparation of conjugates containing a tris(hydroxypyridinone) chelator, and the conjugates retain the uniquely efficient radiolabeling properties reported for the maleimide derivative,^[@ref36]^ affording exceptionally rapid radiochemical synthesis of a ^68^Ga radiopharmaceutical under mild conditions without the need for subsequent purification. Ga^3+^-complexed conjugates of RGD retain affinity for α~v~β~3~ integrin receptors, and provide PET images that allow clear delineation of α~v~β~3~ integrin-positive tumors. The efficiency of labeling tris(hydroxypyridinone) chelators at very low concentrations and under mild conditions brings the possibility of kit-based production of ^68^Ga PET tracers, including sensitive proteins, without complex automated synthesis typical of multistep PET radiochemistry. This would greatly increase ^68^Ga PET access to hospitals that lack expertise or facilities to implement such automated synthetic technologies but are adept in preparation of kit-based radiopharmaceuticals---notably radiopharmacy laboratories routinely producing ^99m^Tc radiopharmaceuticals. Thus, such kit-based technologies will expand the use of the ^68^Ga generator for the benefit of more hospitals and patients.

Experimental Procedures {#sec5}
=======================

Materials and Instrumentation {#sec5.1}
-----------------------------

Chemicals and reagents were obtained from Sigma-Aldrich (Dorset, UK) unless otherwise specified. High-performance liquid chromatography (HPLC) analysis was carried out using an Agilent 1200 LC system with in-line UV and gamma detection (Flow-Count, LabLogic). NMR spectra were acquired on a Bruker Avance 400 spectrometer (Bruker UK Limited, Coventry, UK) equipped with a 5 mm QNP probe at 400.13 MHz for ^1^H NMR spectra (using a zg30 pulse program) and 100.6 MHz for ^13^C NMR spectra (using a zgpg30 pulse program). Spectra were referenced to residual solvent signals. Mass spectra were recorded in the positive ion mode on an Agilent 6510 Q-TOF LC/MS mass spectrometer coupled to an Agilent 1200 LC system (Agilent, Palo Alto, CA). Data were acquired and reference mass-corrected via a dual-spray electrospray ionization source, using the factory-defined calibration procedure. Analytical reverse-phase LCMS and radio-LCMS traces were acquired using an Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a 1 mL min^--1^ flow rate. Instant thin layer chromatography strips (ITLC-SG) were obtained from Varian Medical Systems UK, Ltd. (Crawley, UK), and ITLC strips were visualized using a Raytest Rita-Star TLC scanner. Semipreparative reverse-phase HPLC was conducted using an Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 μm) coupled to an Agilent 1200 LC system, with a 3 mL min^--1^ flow rate and UV spectroscopic detection at 220 nm. Mobile phase A contained water with 0.2% TFA and mobile phase B contained acetonitrile with 0.2% TFA. All methods started with 100% A at 0 min. For method 1, the concentration of B increased at a rate of 1% min^--1^, and for method 2, the concentration of B increased at a rate of 0.5% min^--1^. Analytical reverse-phase HPLC and radio-HPLC traces were acquired using two different instruments: (1) an Agilent 1200 LC system and an Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a 1 mL min^--1^ flow rate and UV spectroscopic detection at either 214 or 220 nm. The radio-HPLC was coupled to a LabLogic Flow-Count detector with a sodium iodide probe (B-FC-3200). Aliquots (10--200 μL) of each radiolabeled sample were injected onto the column, using a flow rate of 1 mL min^--1^. Mobile phase A contained water with 0.1% TFA and mobile phase B contained acetonitrile with 0.1% TFA. For method 3, the concentration of B increased at a rate of 5% min^--1^, with 100% A at 0 min, and 100% B at 20 min. (2) An Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a 1 mL min^--1^ flow rate and UV spectroscopic detection at either 214 or 220 nm coupled to a Shimadzu HPLC consisting of a SCL-10AVP system controller, a SIL-10ADVP autoinjector, a LC-10 ATVP solvent delivery unit, a FCV-10AL control valve, a DGU-14A degasser, and a SPD-10AVP UV detector. This was coupled to a radiation detector consisting of an Ortec model 276 Photomultiplier Base with Preamplifier, Amplifier, BIAS supply and SCA and a Bicron 1 M 11.2 Photomultiplier Tube. For method 4, the concentration of B increased at a rate of 6.67% min^--1^, with 100% A at 0 min, and 80% B at 12 min. For initial radiolabeling and characterization studies that utilized \<400 MBq, an Eckert and Ziegler ^68^Ge/^68^Ga generator (Berlin, Germany) was used. For biodistribution studies, and experiments that utilized \>600 MBq ^68^Ga, an iThemba Laboratories 1.8 GBq ^68^Ge/^68^Ga generator (IDB Holland BV, Netherlands) was used. Analytical size exclusion radio-HPLC traces were acquired using an Agilent 1200 Series HPLC system and a Phenomenex Biosep 2000 (300 × 7.8 mm) size exclusion column with a phosphate buffered saline mobile phase with a flow rate of 1 mL min^−1^.

Synthesis {#sec5.2}
---------

### Compound **2** {#sec5.2.1}

Compound **1** (synthesized according to previously reported procedures^[@ref38]^) (100 mg, 96 μmol) was dissolved in ethanol (5 mL), and carbon disulfide (60 μL, 12 equiv) and triethylamine (13.4 μL, 1 equiv) were added.^[@ref39]^ Addition of water (5 mL) resulted in formation of a white precipitate, corresponding to the dithiocarbamate intermediate. Excess carbon disulfide was removed under reduced pressure, and the remaining solution frozen and lyophilized. The dry residue was resuspended in ethanol (5 mL) containing carbon disulfide (60 μL) and triethylamine (13.4 μL). Di-*tert*-butyl dicarbonate (4 equiv, 21 mg) and 4-dimethylaminopyridine (2--3% molar equiv) were added,^[@ref39]^ and the reaction stirred at room temperature for 6 h. The reaction mixture was evaporated to dryness, the residue dissolved in water/acetonitrile (60%/40%) and applied to a semipreparative reverse-phase Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 μm) with a 3 mL min^--1^ flow rate and UV spectroscopic detection at 220 nm. Using HPLC method 1, **1** eluted with 40% B (40 min). Fractions containing the desired product were lyophilized. Yield = 50 mg, 48%. ^1^H NMR ((CD~3~)~3~SO, 400 MHz): δ 1.80 (m, 6H), 2.05 (m, 6H), 2.45 (t, *J* = 6.37, 2H), 2.55 (s, 9H), 3.75 (broad, 2H), 3.75 (s, 9H), 4.53 (d, *J* = 5.06, 6H), 5.13 (s, 6H), 7.13 (s, 3H), 7.35--7.48 (m, 15H + NH), 8.30 (t, *J* = 5.06, 3NH). ^13^C NMR ((CD~3~)~3~SO, 100 MHz): δ 20.4, 28.9, 29.6, 34.5, 35.4, 38.5, 41.1, 56.6, 74.0, 114.6, 127.5, 128.1, 128.2, 128.3, 136.1, 142.9, 146.3, 151.5, 165.0, 167.9, 171.2. ESI-MS: *m*/*z* for C~59~H~68~N~8~O~10~S + H^+^ calc 1081.48, found 1081.48.

### H~3~THP-NCS {#sec5.2.2}

A solution of chilled boron trichloride in dichloromethane (10 mL, 1 M) was added to a sealed vial containing compound **2** (46 mg, 43 μmol), and the reaction was stirred at ambient temperature for 1 h. The reaction vial was then cooled in an ice bath, and trifluoroethanol (3 mL) was added dropwise to the flask. The reaction solution was evaporated to dryness, and the residue dissolved in water/acetonitrile (80%/20%) and filtered. The filtrate was diluted to 10 mL using a solution of 0.2% TFA in water, and applied to a semipreparative HPLC column. Using HPLC method 2, H~3~THP-NCS eluted with 17--18% B (37 min). Fractions containing the desired product were lyophilized. Yield of trifluoroacetate salt = 25 mg, 47% yield. ^1^H NMR ((CD~3~)~3~SO, 400 MHz): δ 1.82 (m, 6H), 2.08 (m, 6H), 2.45 (t, *J* = 6.41 2H), 2.52 (s, 9H), 3.77 (t, *J* = 6.41, 2H), 3.80 (s, 9H), 4.54 (d, *J* = 5.21, 6H), 6.97 (s, 3H), 7.43 (s, 1NH), 8.47 (t, *J* = 5.21, 3NH). ^13^C NMR ((CD~3~)~3~SO, 100 MHz): δ 20.3, 25.5, 28.8, 34.4, 35.4, 38.3, 41.1, 57.0, 112.4, 127.8, 138.6, 143.2, 148.3, 160.9, 168.2, 173.1. ESI-MS: *m*/*z* for C~38~H~50~N~8~O~10~S + H^+^ calc 811.34, found 811.36.

### Compound **3** {#sec5.2.3}

An excess of *p*-phenylene diisothiocyanate (40 mg) and diisopropylethylamine (40 μL) in DMF (0.5--1 mL) were added to a solution of **1** (40 mg, 39 μmol) in DMF (0.5--1 mL). The reaction solution was agitated, and after 5--10 min, applied to a semipreparative HPLC column. Using HPLC method 1, **3** eluted with 42% B (42 min). Fractions containing the desired product were lyophilized. Yield = 39 mg, 81% yield. ^1^H NMR (CD~3~OD, 400 MHz): δ 1.94 (m, 6H), 2.15 (m, 6H), 2.46 (t, *J* = 6.14, 2H), 2.60 (s, 9H), 3.79 (broad, 2H), 3.84 (s, 9H), 4.60 (s, 6H), 5.20 (s, 6H), 7.17 (d, *J* = 8.79, 2H), 7.33--7.46 (15H), 7.41 (d, *J* = 8.79, 2H). ^13^C NMR (CD~3~OD, 100 MHz): δ 21.4, 30.7, 31.0, 36.5, 36.9, 39.9, 42.1, 59.1, 76.3, 116.2, 125.7, 127.1, 128.6, 129.7, 129.9, 130.0, 136.6, 137.5, 145.0, 148.4, 154.1, 166.6, 173.6, 175.4, 182.0. ESI-MS: *m*/*z* for C~66~H~74~N~10~O~10~S~2~ + 2H^+^ calc 616.26, found 616.26.

### H~3~THP-PhNCS {#sec5.2.4}

A solution of chilled boron trichloride in dichloromethane (5 mL, 1 M) was added to a sealed vial containing compound **3** (20 mg, 16 μmol), and the reaction was stirred at ambient temperature for 1 h. The reaction vial was then cooled in an ice bath, and methanol (5--10 mL) was added dropwise to the flask. The reaction solution was evaporated to near dryness under reduced pressure, and acetone (50 mL) was added to the residue, resulting in a flocculant white precipitate. This suspension was transferred to a 50 mL centrifugal tube, and the mixture centrifuged at 3000 rpm for 10 min. After this, the solution was decanted and discarded, acetone added (50 mL), the suspension agitated, and centrifuged again for 10 min. This process of washing with acetone was repeated again. Finally, the product was dissolved in water/acetonitrile (50/50), filtered, frozen and lyophilized. Yield = 10 mg, 58% yield. ^1^H NMR (CD~3~OD, 700 MHz): δ 1.98 (m, 6H), 2.22 (m, 6H), 2.49 (t, *J* = 6.13 2H), 2.59 (s, 9H), 3.82 (broad, 2H), 3.93 (s, 9H), 4.69 (s, 6H), 7.00 (s, 3H), 7.23 (d, *J* = 8.44, 2H), 7.43 (d, *J* = 8.44, 2H). ^13^C NMR (CD~3~OD, 175 MHz): δ 21.1, 30.6, 31.0, 36.3, 36.9, 39.5, 42.2, 59.1, 114.1, 125.8, 127.2, 128.8, 136.8, 139.4, 140.0, 145.2, 150.4, 162.2, 173.6, 176.3, 182.1. ESI-MS: *m*/*z* for C~45~H~56~N~10~O~10~S~2~ + H^+^ calc 961.37, found 961.37.

### Synthesis of RGD Conjugates {#sec5.2.5}

The cyclic peptide cyclic(RGDfK) (RGD) was dissolved in dimethyl sulfoxide (100--300 μL) and added to a solution of either H~3~THP-NCS or H~3~THP-PhNCS in dimethyl sulfoxide (100--300 μL), and diisopropylethylamine (5--10 μL) was added. The reaction solutions were heated in a microwave (120 °C, 300 W, 30 min) and then applied to a reverse-phase HPLC column. Fractions containing the desired conjugate in sufficient purity were combined and lyophilized. Using HPLC method 2, H~3~THP-NCS-RGD eluted with 21% solvent B (42 min) and H~3~THP-PhNCS-RGD eluted with 23% solvent B (47 min). Isolated yields = 30--40%. H~3~THP-NCS-RGD: ESI-MS: *m*/*z* for C~65~H~91~N~17~O~17~S + 3H^+^ calc 472.22, found 472.22; HPLC: 220 nm, RT = 7.15 min, \>98% purity (HPLC method 3). H~3~THP-PhNCS-RGD: ESI-MS: *m*/*z* for C~72~H~97~N~19~O~17~S~2~ + 3H^+^ calc 522.23, found 522.24; HPLC: 220 nm, RT = 7.80 min, \>98% purity (HPLC method 3).

Complexing H~3~THP-NCS-RGD and H~3~THP-PhNCS-RGD with ^68^Ga^3+^ and ^*nat*^Ga^3+^ {#sec5.3}
----------------------------------------------------------------------------------

Initial radiolabeling experiments utilized an Eckert & Ziegler ^68^Ge/^68^Ga generator. Aqueous HCl solution (0.1 M, 5 mL) was passed through the generator and the eluate was fractionated (5 × 1 mL). The second fraction (1 mL, containing 90--100 MBq ^68^Ga) was added directly to an ethanol/water solution (50%/50%, 50--100 μL) of either H~3~THP-NCS-RGD (22.5 μg) or H~3~THP-PhNCS-RGD (25 μg), immediately followed by a solution of ammonium acetate (1 M, 300 μL). This solution was immediately applied to an analytical reverse-phase C18 HPLC column. \[^68^Ga(THP-NCS-RGD)\]: radiochemical yield \>99% (HPLC), HPLC: RT = 7.83 min (HPLC method 3). \[^68^Ga(THP-PhNCS-RGD)\]: radiochemical yield \>99% (HPLC), HPLC: RT = 8.15 min (HPLC method 3). For both conjugates, specific activity at calibration = 8--9 MBq nmol^--1^ conjugate.

The nonradioactive analogues, \[^*nat*^Ga(THP-NCS-RGD)\] and \[^*nat*^Ga(THP-PhNCS-RGD)\], were also prepared. An aqueous solution of GaCl~3~ (2 mg mL^--1^, 5 μL, 50--60 nmol) was added to either H~3~THP-NCS-RGD (45 μg, ∼24 nmol) or H~3~THP-PhNCS-RGD (50 μg, ∼25 nmol) dissolved in deionized water (50 μL). The solutions were applied to an analytical reverse-phase C18 HPLC column and subjected to LCMS analysis. \[^*nat*^Ga(THP-NCS-RGD)\]: HPLC RT = 7.57 min (HPLC method 3); MS C~65~H~88~N~17~O~17~SGa + 2H^+^, observed monoisotopic peak = 740.78, calculated =740.78. \[^*nat*^Ga(THP-PhNCS-RGD)\]: HPLC RT = 8.15 min (HPLC method 3); MS C~72~H~94~N~19~O~17~S~2~Ga + 2H^+^, observed monoisotopic peak = 815.80, calculated 815.80.

For biodistribution studies, ^68^Ga eluate from an iThemba Lab generator was preconditioned as previously described.^[@ref41]^ Briefly, a cation exchange cartridge containing AG 50W×4 resin (50 mg) was conditioned by passing through aqueous HCl solution (4 M, 1 mL) and deionized water (1 mL) sequentially. To elute the ^68^Ge/^68^Ga generator, aqueous HCl solution (0.4 M, 5 mL) was passed through the generator and transferred directly onto the cation exchange cartridge. The cartridge was dried with air (1 mL), washed with 0.15 M HCl in water/ethanol (20%/80%), and again dried with air (1 mL). A solution of 0.9 M HCl in water/ethanol (200 μL, 10%/90%) was used to elute ^68^Ga (800--1000 MBq), which was diluted to a volume of 1 mL with deionized water. Lyophilized peptide conjugate---H~3~THP-NCS-RGD (22.5 μg, trifluoroacetate salt) or H~3~THP-PhNCS-RGD (25 μg, trifluoroacetate salt)---dissolved in 20--40 μL of water/ethanol (50%/50%) was added to the solution containing ^68^Ga, immediately followed by a solution of ammonium acetate (2 M, 400 μL) and 0.9% saline (1100 μL). An aliquot for ITLC analysis was immediately applied to an ITLC-SG plate. The ITLC-SG plate was developed using an aqueous citrate buffer (0.1 M, pH 5.5) mobile phase. \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\]: *R*~f~ \< 0.1; \[^68^Ga(citrate)~2~\]^3--^: *R*~f~ \> 0.8. \[^68^Ga(THP-NCS-RGD)\]: radiochemical yield = 96--98% (ITLC), HPLC: RT = 9.42 min (HPLC method 4). \[^68^Ga(THP-PhNCS-RGD)\]: radiochemical yield = 97--99% (ITLC), HPLC: RT = 9.78 min (HPLC method 4). For both conjugates, specific activity at dose measurement = 60--80 MBq nmol^--1^ conjugate.

Serum Stability Studies {#sec5.4}
-----------------------

Solutions containing \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] (each 250 μL, containing 50 MBq ^68^Ga^3+^ and ∼5 μg of peptide conjugate, synthesized using eluate from an Eckert and Ziegler generator as described above) were added to 1.25 mL of fresh human female O^+^ serum, and incubated at 37 °C for 4 h. At 1 and 4 h, aliquots were applied to a size exclusion HPLC column. Solutions of \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] were also separately subjected to size exclusion chromatographic analysis to determine retention times. A solution of ^68^Ga^3+^ in 0.33 M ammonium acetate (10 MBq, 50 μL) was added to 250 μL of serum and incubated at 37 °C for 1 h to determine the retention time of ^68^Ga^3+^-bound serum proteins.

Metabolic Stability Studies {#sec5.5}
---------------------------

Solutions containing \[^68^Ga(THP-NCS-RGD)\] and \[^68^Ga(THP-PhNCS-RGD)\] (synthesized using eluate from an Eckert and Ziegler generator as described above) were diluted with physiological saline solution (15--30 MBq of each radiotracer containing 1--3 μg conjugate) and administered intravenously to seven- to nine-week-old female Balb/c mice (Harlan, UK) under isoflurane anesthesia. At 20 or 90 min PI, animals were euthanized, and serum and urine samples collected and analyzed using analytical reverse-phase HPLC (method 3).

Determination of IC~50~ {#sec5.6}
-----------------------

The relative affinity of \[Ga(THP-NCS-RGD)\], \[Ga(THP-PhNCS-RGD)\], and RGD for integrin α~v~β~3~ was determined in a solid-phase competitive binding assay^[@ref45],[@ref47]^ with ^125^I-echistatin (PerkinElmer, Boston). In brief, wells of a 96 well plate were coated with integrin α~v~β~3~ (150 ng mL^--1^) in coating buffer (100 μL, 25 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM CaCl~2~, 0.5 mM MgCl~2~, and 1 mM MnCl~2~) overnight at 4 °C. Wells were then washed twice in binding buffer (coating buffer containing 0.1% bovine serum albumin (w/v) (BSA)) before being blocked for 2 h at room temperature with blocking buffer (coating buffer containing 1% BSA (w/v)). After a further two washes in binding buffer, ^125^I-echistatin (0.5 kBq) and \[Ga(THP-NCS-RGD)\], \[Ga(THP-PhNCS-RGD)\], or RGD were added simultaneously (to a total volume of 100 μL, and a conjugate/(RGDfK) concentration of 10 000 nM to 0.001 nM) for 1 h at room temperature, before being washed twice as before. Finally, the amount of activity bound to the wells via integrin α~v~β~3~ was counted using a Wallac 1282 Compugamma Universal Gamma Counter. Measurements at each concentration for each compound were obtained in sextuplicate. IC~50~ values were calculated using a nonlinear regression model (Binding/Saturation, one site--total) in GraphPad Prism 5.04.

PET Scanning and Biodistribution {#sec5.7}
--------------------------------

All animal experiments were performed with approval from the Peter MacCallum animal ethics committee. Six- to eight-week-old Balb/c nude mice (Animal Resources Centre, Western Australia) were implanted subcutaneously on the right flank with 4 million U87MG cells. Once the tumors reached a volume of \>250 mm^3^ the animals were injected intravenously with 13--20 MBq \[^68^Ga(THP-NCS-RGD)\] (containing 1 μg of H~3~THP-NCS-RGD). For blocking studies, animals were coinjected with RGD peptide (400 μg). At 1 and 2 h, the animals were anaesthetized and imaged on a Philips MOSAIC small animal PET scanner. The images were reconstructed using a 3D RAMLA algorithm and tracer uptake determined as described previously.^[@ref48]^ On completion of the scan animals were euthanized and tissues harvested, weighed, and radioactivity counted using a Gamma Counter (Biomedex).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.bioconjchem.5b00335](http://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.5b00335).HPLC chromatograms, serum stability, metabolic stability and biodistribution data ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.5b00335/suppl_file/bc5b00335_si_001.pdf))
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